Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Poll

December 01, 2011

Molecular Diagnostic Reimbursement

Companies are facing significant challenges in gaining provider acceptance and reimbursement for molecular diagnostics, which are the hallmark of personalized medicine. Steven Burrill, CEO of Burrill & Company, even likened gaining acceptance for personalized medicine diagnostics to hand-to-hand combat: “Investors were naïve at how substantial and perverse the resistance to adoption is.” Some companies are prevailing, however, through strategies that include obtaining a dedicated current procedural terminology (CPT) code, gaining acceptance of diagnostics as a standard of care, and forming partnerships with the pharmaceutical industry. Others are concentrating efforts on developing diagnostics for the ex-U.S. market. How is your company handling this issue?

How is your company overcoming reimbursement hurdles for molecular diagnostics in the U.S.?

  {{ choice.Percent }}%